Moors & Cabot, Inc. Astrazeneca PLC Transaction History
Moors & Cabot, Inc.
- $2.05 Billion
- Q2 2025
A detailed history of Moors & Cabot, Inc. transactions in Astrazeneca PLC stock. As of the latest transaction made, Moors & Cabot, Inc. holds 8,014 shares of AZN stock, worth $688,162. This represents 0.03% of its overall portfolio holdings.
Number of Shares
8,014
Previous 8,036
0.27%
Holding current value
$688,162
Previous $590,000
5.08%
% of portfolio
0.03%
Previous 0.03%
Shares
36 transactions
Others Institutions Holding AZN
# of Institutions
1,412Shares Held
496MCall Options Held
7.11MPut Options Held
2.56M-
Price T Rowe Associates Inc Baltimore, MD51.9MShares$4.46 Billion0.41% of portfolio
-
Primecap Management CO Pasadena, CA41.2MShares$3.54 Billion2.35% of portfolio
-
Wellington Management Group LLP Boston, MA34.3MShares$2.95 Billion0.45% of portfolio
-
Capital International Investors Los Angeles, CA31.4MShares$2.7 Billion0.39% of portfolio
-
Bank Of America Corp Charlotte, NC31.2MShares$2.68 Billion0.16% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $266B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...